PrescribedRX review

Many telehealth platforms answer the state question with "confirmed at intake", which means completing a health questionnaire to find out you are ineligible. PrescribedRX puts the answer on the product page: injectable testosterone is unavailable in California, Colorado, Iowa, Washington and Wisconsin, and enclomiphene in Alabama and South Carolina. Pricing is equally plain — $139 a month, or $387 for three months at $129 a month, same price at every dose, with a blood test at $69. It names the clinicians behind the prescribing, through its telehealth partner Telegra MD. What it will not tell you is who compounds the medication, and its refund terms are much narrower than the money-back line on the plan pages.

PrescribedRX (PrescribedRx, LLC of West Palm Beach, Florida) is a multi-condition telehealth brand covering five lines: Increase Testosterone (enclomiphene, injectable testosterone, testosterone cream), Weight Loss (compounded semaglutide and tirzepatide injectables), Hair Loss, Sexual Health and Longevity, which carries sermorelin, NAD+ and glutathione in injectable and nasal forms. It describes itself as a patient-management and marketing platform: it does not employ the prescribers or dispense medication, and care is delivered by clinicians of a third-party medical group, Telegra MD. Its testosterone plans are sold as monthly or three-month packages with monthly home delivery and ongoing dose support, beginning with a blood test.

Asynchronous with a blood test at the front. You take a blood test, at home or at a lab, for $69 against a struck-through $119; the plan pages say it covers total testosterone, hematocrit, PSA and LH. A licensed provider reviews it, and if approved your plan ships monthly with ongoing support and secure messaging with the care team. Flat dose pricing is stated explicitly, so an increase in dose does not increase the bill, which matters on testosterone where titration is normal. The disclosure that sets it apart is geographic: rather than deferring to intake, each product page names the states it cannot serve. That is a small thing that saves real time, and it is also a signal of a platform willing to publish an inconvenient fact. The clinical side is identified: its About page names Telegra MD's chief medical officer, Takashi Nakamura, MD, its medical director, Laurie J. Mercier, MD, and three further clinicians, and states they are employed by Telegra MD rather than PrescribedRX. A LegitScript seal is displayed in the footer. The gaps that remain matter for an open-ended hormone prescription. No compounding pharmacy is named, only "licensed U.S. pharmacies". And the plan pages promise a money-back guarantee that the purchase terms narrow sharply: a full refund if a provider declines to prescribe, an administrative fee of up to $99 if you cancel before the consultation, and no refund at all once a prescription goes to the pharmacy.

Published openly on each plan page with both tiers visible. Injectable testosterone is $139 a month on the monthly plan or $387 for three months, which the site states as $129 a month, both shown against higher struck-through figures. Enclomiphene and the testosterone cream carry the same $139 monthly and $387 three-month structure. The blood test is $69. Same price at every dose is stated verbatim, along with no waitlist and no hidden fees, free priority shipping and a money-back guarantee, though the purchase terms make orders non-refundable once a prescription is sent to the pharmacy and allow minimum commitments on some therapies. $139 is the true month-to-month rate rather than a prepay headline, and the discount tier is disclosed rather than disguised. On the weight-loss side, compounded semaglutide is $189/mo and tirzepatide $276/mo month to month, but those are GLP-1 numbers and are not a testosterone price. What is not stated is whether the ongoing monitoring labs testosterone therapy requires are covered after the initial $69 test.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. The testosterone plan pages state that the medications are compounded preparations not reviewed or approved by the FDA for safety or effectiveness. PrescribedRX does not name its compounding pharmacies, and compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are. On the evidence, testosterone replacement has the strongest evidence base of the therapies sold here: the underlying molecule has a large randomized safety base, including a major cardiovascular safety trial, and it produces reliable changes in serum testosterone, lean mass and sexual function in men with genuinely low levels. That evidence does not excuse loose monitoring. Therapy suppresses your own production, raises hematocrit in a meaningful minority of men, requires PSA surveillance, and is a long-term commitment rather than a course. Enclomiphene is the alternative route offered here — a selective estrogen receptor modulator that raises endogenous testosterone by increasing LH and FSH, which preserves fertility in a way exogenous testosterone does not, and which has smaller and shorter trials behind it than testosterone itself. Neither choice should be made from a website. Individual results vary.